Condition

Pancreatic Insufficiency

ClinicalTrials.gov condition label

Clinical trials6

Recruiting3

Common interventions8

Lead sponsors shown4

Clinical trials

6 shown

Dorzagliatin in Pancreatic Insufficient Cystic FibrosisNCT06995651 · 2025-10-21

RECRUITING

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceNCT04731272 · 2021-07-16

RECRUITING

Beta-cell Response to Incretin Hormones in Cystic FibrosisNCT01851694 · 2013-05-01

RECRUITING

Pancreatic Exocrine Insufficiency After Bariatric SurgeryNCT03279653 · 2017-09-01

UNKNOWN

Effect of Chronic Incretin-based Therapy in Cystic FibrosisNCT01879228 · 2013-06-01

COMPLETED

Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic FibrosisNCT00763412 · 2006-11-01

COMPLETED

Common interventions

placeboDRUG3DorzagliatinDRUG1Dulaglutide 0.75Mg/0.5Ml Inj PenDRUG1GIPDRUG1GLP-1DRUG1repaglinideDRUG1SitagliptinDRUG1SleeveGastrectomyPROCEDURE1

Leading sponsors

University of Pennsylvania3Arbelaez, Ana Maria1Michael R. Rickels, MD, MS1Umraniye Education and Research Hospital1

Trial status mix

RECRUITING3

COMPLETED2

UNKNOWN1

Phase mix

NA3

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.